Abstract
Inflammatory bowel diseases (IBD) are idiopathic chronic inflammations: the etiology of Crohns disease (CD) and ulcerative colitis (UC) is still largely unknown. Environmental and genetic factors in combination with the microbial flora or specific microorganisms trigger an event, leading to the activation of an intestinal immune response. Immune and non-immune cells create a cross talk via the secretion of soluble mediators and expression of cell adhesion molecules, resulting in further cell activation. Mediators such as cytokines and chemokines play a role in cell recruitment and polarization, intercellular signal amplification or activation and differentiation. Considering these aspects, medical management of inflammatory bowel disease has changed considerably over the past decade. Advances in biotechnology has allowed for the introduction of many biologic therapies, other than anti-TNF therapies. Many of these drugs showed clinical benefit for induction and maintenance therapy, both in UC and CD. Although numerous, at present only monoclonal anti-TNF antibodies are currently available worldwide. Other biological agents have been tested or are under evaluation. This paper systematically reviews the mechanism-of-action, efficacy, short-term and, where available, long-term safety of biological agents that have been approved for the treatment of IBD or are under evaluation which target different molecules other than tumor necrosis factor α (TNF-α).
Current Drug Targets
Title: Emerging Biologics in the Treatment of Inflammatory Bowel Disease: What is Around the Corner?
Volume: 11 Issue: 2
Author(s): Gionata Fiorino, Serena Rovida, Carmen Correale, Alberto Malesci and Silvio Danese
Affiliation:
Abstract: Inflammatory bowel diseases (IBD) are idiopathic chronic inflammations: the etiology of Crohns disease (CD) and ulcerative colitis (UC) is still largely unknown. Environmental and genetic factors in combination with the microbial flora or specific microorganisms trigger an event, leading to the activation of an intestinal immune response. Immune and non-immune cells create a cross talk via the secretion of soluble mediators and expression of cell adhesion molecules, resulting in further cell activation. Mediators such as cytokines and chemokines play a role in cell recruitment and polarization, intercellular signal amplification or activation and differentiation. Considering these aspects, medical management of inflammatory bowel disease has changed considerably over the past decade. Advances in biotechnology has allowed for the introduction of many biologic therapies, other than anti-TNF therapies. Many of these drugs showed clinical benefit for induction and maintenance therapy, both in UC and CD. Although numerous, at present only monoclonal anti-TNF antibodies are currently available worldwide. Other biological agents have been tested or are under evaluation. This paper systematically reviews the mechanism-of-action, efficacy, short-term and, where available, long-term safety of biological agents that have been approved for the treatment of IBD or are under evaluation which target different molecules other than tumor necrosis factor α (TNF-α).
Export Options
About this article
Cite this article as:
Fiorino Gionata, Rovida Serena, Correale Carmen, Malesci Alberto and Danese Silvio, Emerging Biologics in the Treatment of Inflammatory Bowel Disease: What is Around the Corner?, Current Drug Targets 2010; 11 (2) . https://dx.doi.org/10.2174/138945010790309975
DOI https://dx.doi.org/10.2174/138945010790309975 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treatment of Cardiovascular Risk Factors in Women
Current Medicinal Chemistry Isolated Perioperative Hypertension: Clinical Implications & Contemporary Treatment Strategies
Current Hypertension Reviews Nummular Eczema: An Updated Review
Recent Patents on Inflammation & Allergy Drug Discovery Recent Advancements in the Therapeutics of Food Allergy
Recent Patents on Food, Nutrition & Agriculture The Role of Anaphylatoxins C3a and C5a in Regulating Innate and Adaptive Immune Responses
Inflammation & Allergy - Drug Targets (Discontinued) Life Threatening and Fatal Contrast Media Reactions: Pathomechanisms, Diagnosis, Prevention and Drug Management
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Symptoms, Diagnosis, and Treatment of Cow's Milk Allergy
Current Pediatric Reviews Resurgence of Herbal Antihypertensives in Management of Hypertension
Current Hypertension Reviews Irbesartan and Hydrochlorothiazide Association in the Treatment of Hypertension
Current Vascular Pharmacology Cross-Reactive Reactions to Nonsteroidal Anti-Inflammatory Drugs
Current Pharmaceutical Design Potassium Channel Openers and Improvement of Toxic Stress: Do they have Role in the Management of Inflammatory Bowel Disease?
Inflammation & Allergy - Drug Targets (Discontinued) A Systematic Review of Randomized Controlled Trials Examining the Nephroprotective Properties of Antihypertensive Medications
Current Hypertension Reviews An Update on the Roles of the Complement System in Autoimmune Diseases and the Therapeutic Possibilities of Anti-Complement Agents
Current Drug Therapy Serine Proteinase Inhibitors in the Skin: Role in Homeostasis and Disease
Current Protein & Peptide Science Structure Function Analysis of Serpin Super-Family: "A Computational Approach"
Protein & Peptide Letters Meet the Editorial Board Member
Recent Patents on Inflammation & Allergy Drug Discovery Adverse Drug Reaction Labelling for Atomoxetine, Methylphenidate and Modafinil: Comparison of Product Information for Oral Formulations in Australia, Denmark and the United States
Current Drug Safety Cutaneous Adverse Reactions to Amoxicillin-Clavulanic Acid Suspension in Children: The Role of Sodium Benzoate
Current Drug Safety Editorial
Current Enzyme Inhibition Anabolic-androgenic Steroid use and Psychopathology in Athletes. A Systematic Review
Current Neuropharmacology